{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041368","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.869480+00:00","generated_at":"2026-06-11T19:23:35.940081+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tyra Biosciences Q2 net loss $13.3M; orphan drug designation for TYRA-300 in achondroplasia","bullets":["Net loss $13.3M vs $15.1M Q2 2022; cash & equivalents $232.4M as of June 30.","FDA granted Orphan Drug Designation for TYRA-300 for achondroplasia in July 2023.","SURF301 Phase 1/2 oncology study enrollment ongoing in Part A and Part B at U.S., EU, Australia sites.","TYRA-200 Phase 1 study in intrahepatic cholangiocarcinoma on track to dose first patient 2H 2023.","Strengthened leadership: appointed Dr. Michael Bober as VP Clinical Development and Medical Affairs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041368","json":"https://secwatch.observer/filing/0000950170-23-041368.json","markdown":"https://secwatch.observer/filing/0000950170-23-041368.md","text":"https://secwatch.observer/filing/0000950170-23-041368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000095017023041368/0000950170-23-041368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000095017023041368/tyra-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:23:35.940081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c12b935c45db5bd750f75e7580d751b089ed2bbf","claim":"Tyra Biosciences, Inc. reported the quarter ended June 30, 2023 results: net income Second quarter 2023 net loss was $13.3 million.","evidence_excerpt":"Second quarter 2023 net loss was $13.3 million compared to $15.1 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017023041368/0000950170-23-041368-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Second quarter 2023 net loss was $13.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}